ABOUT US
|
OSIVAX is a biotech company developing vaccines and immunotherapies inducing powerful CD8+ T cell responses thanks to its breakthrough technology platform, oligoDOM®
In 2017, IMAXIO's leadership team took the opportunity to invest their time and reputation into oligoDOM®, a promising technology platform |
|
oligoDOM® technology platform leverages on:
OSIVAX’ leading program is a universal influenza vaccine candidate about to start a phase I clinical trial. This vaccine will be combined with conventional seasonal vaccines to fill the current unmet medical need for patients > 65 years old (for whom vaccine effectiveness is below 35%).
OSIVAX remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens.
- Twelve years of R&D on a breakthrough approach to induce CD8+ T cell immunity
- A promising leading candidate of universal influenza vaccine
- Additional development opportunities, especialy in cancer immunotherapies
OSIVAX’ leading program is a universal influenza vaccine candidate about to start a phase I clinical trial. This vaccine will be combined with conventional seasonal vaccines to fill the current unmet medical need for patients > 65 years old (for whom vaccine effectiveness is below 35%).
OSIVAX remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens.